Basel, Switzerland and Romainville, France, June 8th, 2009 – The contract biomanufacturing organization Celonic AG and the genome customization company Cellectis BioResearch, have announced the signature of a commercial license agreement on Celonic’s patented meganuclease-based CEMAX® technology.
Celonic AG, Basel, and APIT Laboratories GmbH, Potsdam, announce a commercial license agreement for of a new biopharmaceutical compound for the treatment of cancer.